.svg){kind=small}
Many "normal" healthy volunteers will actually have abnormal ECG's at times or indeed have abnormal ECG's which are missed. These abnormal ECG's may have a big impact on the development of a new chemical entity if the data obtained is not scrutinised properly at an early stage.
As such early signal detection and full follow up by Richmond Pharmacology's cardiology team, lead by Professor Camm, is essential to ensure that the digital ECG data obtained from an early phase trial is analysed and reported appropriately.
Richmond Pharmacology has the capacity to undertake and subsequently analyse a number of cardiological assessments in order to understand and explain abnormal ECG data obtained during a clinical study of a new chemical entity. Our offering of an in house clinic trials unit and cardio analysis services all under one roof makes, Richmond Pharmacology the only choice for studies where the cardio profile of a compound may be in question.
Analysis services include rest and exercise ECG analysis, detailed QT analysis, entry criteria validation, and cardiac event classification and Holter provision, analysis and review. Drug development range of services cover phase I-IV ECG safety studies for cardiovascular and non-cardiovascular compounds. Rest, exercise and QT digitized ECG analysis are performed using Richmond's bespoke and integrated MUSE setup.
